These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17545536)

  • 1. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
    Lewis LD; Miller AA; Rosner GL; Dowell JE; Valdivieso M; Relling MV; Egorin MJ; Bies RR; Hollis DR; Levine EG; Otterson GA; Millard F; Ratain MJ;
    Clin Cancer Res; 2007 Jun; 13(11):3302-11. PubMed ID: 17545536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
    Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
    Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
    Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
    Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
    Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
    Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
    Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
    Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
    Cox MC; Low J; Lee J; Walshe J; Denduluri N; Berman A; Permenter MG; Petros WP; Price DK; Figg WD; Sparreboom A; Swain SM
    Clin Cancer Res; 2006 Aug; 12(15):4636-40. PubMed ID: 16899612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients.
    Tornatore KM; Brazeau D; Dole K; Danison R; Wilding G; Leca N; Gundroo A; Gillis K; Zack J; DiFrancesco R; Venuto RC
    J Clin Pharmacol; 2013 Oct; 53(10):1039-47. PubMed ID: 23908147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
    Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
    J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
    Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
    Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
    Zamboni WC; Combest AJ; DeLoia JA; Edwards RP; Bridges AS; Zamboni BA; Walko CM; Yu AY; Krivak TC; Kelley JL
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1255-62. PubMed ID: 21437702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD; Cho HY; Lee YB
    Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
    Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.